SUD Scoop Series
Each 30-minute webinar offers a dynamic, peer-driven discussion focused on complex substance use disorder cases. Free to AAPP members! Click the link to learn more and register.
Searching for Solutions
Member News: October 2025
The important work of AAPP member Mark Schneiderhan is highlighted in this article as are the funding cuts that will reduce access to these services and impact the training of new clinicians.
Brianna Englett was promoted to Director of Pharmacy for Cardinal Health.
Megan Ehret completed the AACP Academic Leadership Fellows Program (AFLP).
Improving medication-related outcomes for patients with psychiatric and neurologic disorders: Value of psychiatric pharmacists as part of the health care team
There is a shortage of psychiatric pharmacy providers, and patients have unmet needs that can be filled by these individuals. AAPP's position paper describes the expertise and skills of psychiatric pharmacists and the associated positive outcomes for patients with these disorders. This paper also outlines barriers to the provision of services by psychiatric pharmacists and presents action items aimed at effecting change. Read this position paper to learn more about the value of psychiatric pharmacists as part of the health care team. We hope you will consider exploring psychiatric pharmacy for your career.
AAPP Participates in September JCPP Meeting
The Joint Commission of Pharmacy Practitioners (JCPP), a forum of thirteen national pharmacy organizations that addresses topics impacting the profession of pharmacy, met on September 30, 2025, in Alexandria, Virginia, for its annual fall meeting. During this meeting, JCPP focused on building consensus to advance pharmacists’ patient care roles and tackle evolving workforce, business, and health plan challenges in pharmacy. The meeting agenda included discussion of:
CMMI Releases Report on Maternal Opioid Misuse (MOM) Model
The CMS Innovation Center recently released evaluation reports and publications related to the MOM Model, a patient-centered service delivery model that aims to improve the quality of care for pregnant and postpartum Medicaid beneficiaries with opioid use disorder (OUD) and their infants. The reports acknowledge that MOM Model beneficiaries faced complex and overlapping health, behavioral and social challenges that demanded flexible, trauma-informed care. The reports cite promising practices emerging that demonstrate how states can advance integrated care for pregnant and postpartum individuals with opioid use disorder in Medicaid by aligning services with patients’ full range of medical, behavioral and social needs.
Grant Payments: Grant awards will be paid with a mailed check. All grant awards will be paid in full (100%) in 1 single payment, unless the grant application specifies otherwise. Overhead, Facilities, & Administration Fees: As an approved 501(c)3 organization, the AAPP Foundation's policy is to not pay overhead, facilitates, or administration fees. These fees should not be included in grant budgets.
No summary available
Psychiatric pharmacists are advanced practice clinical pharmacists committed to being part of an interdisciplinary team treating substance use disorders often in combination with serious mental illness. AAPP members have authored numerous substance use disorder toolkits, documents, and educational activities to further the knowledge of pharmacists and other health care professionals.
Advocating for Mood Stabilizers for Bipolar Disorder – A Gold Standard Treatment
AAPP supports access to mood stabilizers, including lithium, for the treatment of bipolar disorder. Use AAPP’s policy brief to support your own advocacy for this gold-standard treatment (member only resource).
Psychiatric Pharmacy Specialty Mock Exam for BCPP Candidates
Studying for the BCPP exam? Test your knowledge with our 150-question mock exam! #psychpharmacy #BCPP #AAPP #BPS #boardcertification
Goals for Opioid Use Disorder Medications — Protection, Remission, and Recovery
There has been confusion and controversy about the appropriate clinical goals for the use of medications such as methadone and buprenorphine. A key question has been when, if ever, to taper and discontinue medication.
Low-Threshold Buprenorphine in Non-Traditional Settings: A Scoping Review
This review aims to describe approaches taken by programs in non-clinical settings by identifying key components of delivery models, implementation barriers and facilitators, and outcomes.
AHRQ Medications for Opioid Use Disorder Playbook
A practical guide for providing medications for opioid use disorder (MOUD) and immediate care for patients with opioid use disorder (OUD) in primary care and other ambulatory care settings.
What I Wish I Knew - Talking the Talk: Discussing Illicit or Non-Prescription Drug Use with Patients
Dr. Raeschell Williams, PharmD, BCPS, BCPP, explains how to discuss illicit or non-prescription drug use with patients.